title: Postoperative metyrapone test in the early assessment of outcome of pituitary surgery for Cushing's disease.
abstract: OBJECTIVE
  The prediction of relapse during the early months after transsphenoidal surgery for Cushing's disease remains difficult. We have evaluated the usefulness of the postoperative metyrapone test in this situation.
  
  
  METHODS
  From a retrospective series of 77 consecutive primary pituitary operations for Cushing's disease 29 patients, who also had a metyrapone test at 14 days postoperatively, were selected. Median follow-up was 35 months (range: 8-118 months).
  
  
  METHODS
  Early postoperative: fasting morning serum cortisol, 24-hour urinary cortisol excretion, serum 11-deoxycortisol after 6 x 750 mg metyrapone. Remission was defined as a fasting morning serum cortisol < 140 nmol/l and/or 24-hour urinary cortisol excretion < 250 nmol. During follow-up: serum cortisol, as well as serum cortisol in the 1 mg overnight dexamethasone-suppression test was measured in order to detect relapse of Cushing's disease.
  
  
  RESULTS
  Twelve of 29 patients were not in remission after surgery. These patients all had serum 11-deoxycortisol levels > 350 nmol/l after metyrapone. Seventeen patients met the criteria for early remission. Four of these patients had serum 11-deoxycortisol levels between 150 nmol/l and 350 nmol/l after metyrapone. Three of these 4 patient's experienced a relapse of Cushing's disease during follow-up. In the 13 patients with a serum 11-deoxycortisol < 150 nmol/l after metyrapone, no relapse occurred.
  
  
  CONCLUSIONS
  The metyrapone test is a useful test in the assessment of outcome of pituitary surgery for Cushing's disease, with a sensitivity of 100% and a specificity of 75% for the early detection of patients at risk of a relapse. Patients in whom a serum 11-deoxycortisol > 150 nmol/L is found after metyrapone are at a high risk for relapse of Cushing's disease.
authors.affiliation: Department of Internal Medicine III, University Hospital Rotterdam, The Netherlands.
authors.forename: M O
authors.initials: MO
authors.lastname: van Aken
authors.forename: W W
authors.initials: WW
authors.lastname: de Herder
authors.forename: A J
authors.initials: AJ
authors.lastname: van der Lely
authors.forename: F H
authors.initials: FH
authors.lastname: de Jong
authors.forename: S W
authors.initials: SW
authors.lastname: Lamberts
mesh_terms: D000293:Adolescent; D000328:Adult; D003350:Cortodoxone / Q000097:blood; D003480:Cushing Syndrome / Q000175:diagnosis* / Q000601:surgery*; D003907:Dexamethasone; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000652:urine; D008297:Male; D008797:Metyrapone; D008875:Middle Aged; D010902:Pituitary Gland / Q000503:physiopathology / Q000601:surgery*; D011184:Postoperative Period; D011237:Predictive Value of Tests; D012008:Recurrence; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D003907:Dexamethasone; D003350:Cortodoxone; D006854:Hydrocortisone; D008797:Metyrapone